June 2026

This analysis compared health care resource utilization and costs for Medicaid patients with serious mental illness between US states with low vs high reimbursement rates for psychiatric services.

Greater reliance on travel nurses may be associated with more hospital complications.

This article evaluates the programmatic cost of 3 behavioral mobile messaging interventions aimed at improving cardiovascular medication adherence in The Nudge Study.

The authors evaluated changes in persistence to basal insulin in a Medicare Advantage population in the first year of the Medicare insulin out-of-pocket cost cap.

Veterans with Alzheimer disease (AD), identified using clinical notes, have higher health care utilization than veterans without AD.

In this real-world study of patients with type 2 diabetes, treatment with semaglutide resulted in greater reductions in body weight and hemoglobin A1c than dulaglutide.

The authors describe Medicare Advantage plans that screen for and provide supplemental benefits addressing social needs and explore how these benefits meet communities’ social needs.

A cross-sectional study of online financial documents among hospitals in linguistically diverse core-based statistical areas found that nonprofit and system-affiliated hospitals have superior language access.

Food insecurity among working-age US adults has significant economic consequences, primarily driven by increased job instability and income insecurity.

Research indicates that prior authorizations for drugs take physician practices and pharmacies 15 to 64 minutes to complete and cost $15 to $63 each.

The combination of pharmacotherapy and psychotherapy is associated with reductions in emergency department visits and inpatient admissions along with lower total cost of care relative to either therapy alone.

This article provides a commentary on a news feature published on AJMC.com in 2025 titled “AI Seen as Key to Reducing Health Care Claim Denials, Survey Finds.”

A reproducible Prior Authorization Friction Index enables payers to identify glucagon-like peptide-1 delays and rework, reduce avoidable barriers, and monitor utilization, budgets, and equity in real-world practice.